Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
Titel:
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
Auteur:
Boku, Narikazu Omori, Takeshi Shitara, Kohei Sakuramoto, Shinichi Yamaguchi, Kensei Kato, Ken Kadowaki, Shigenori Tsuji, Kunihiro Ryu, Min-Hee Oh, Do-Youn Oh, Sang Cheul Rha, Sun Young Lee, Keun-Wook Chung, Ik-Joo Sym, Sun Jin Chen, Li-Tzong Chen, Jen-Shi Bai, Li-Yuan Nakada, Takashi Hagihara, Shunsuke Makino, Reina Nishiyama, Eiji Kang, Yoon-Koo